ArticleThe international journal of neuropsychopharmacology2012
Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder.
Article in The international journal of neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Trial
- A randomized placebo-controlled PET study of ketamine´s effect on serotoninTranslational psychiatry · 2020Trial
- Convergent increases in serotonin 1B receptor binding following ketamine and electroconvulsive therapy: a multi-centre bayesian re-analysis of PET data.Molecular psychiatry · 2026Article
- When Standard Is Not Enough: A Narrative Review of Supratherapeutic SSRI Doses in Resistant Obsessive Compulsive Disorder.Journal of clinical medicine · 2025Review
- Altered Serotonin 1B Receptor Binding After Escitalopram for Depression Is Correlated With Treatment Effect.The international journal of neuropsychopharmacology · 2024Article
- The utility of PET imaging in depression.Frontiers in psychiatry · 2024Review
- Is serotonin transporter brain binding associated with the cortisol awakening response? An independent non-replication.PloS one · 2023Article
- ABCB1 variants and sex affect serotonin transporter occupancy in the brain.Molecular psychiatry · 2022Article
- In vivo correlation of serotonin transporter and 1B receptor availability in the human brain: a PET study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2021Review
- Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression.Neuropharmacology · 2021Article
- PET technology for drug development in psychiatry.Neuropsychopharmacology reports · 2020Review
- Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2.The international journal of neuropsychopharmacology · 2019Article
- Serotonin and Norepinephrine Transporter Occupancy of Tramadol in Nonhuman Primate Using Positron Emission Tomography.The international journal of neuropsychopharmacology · 2019Article
- Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [Clinical pharmacokinetics · 2017Article
- Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.Psychopharmacology · 2015Article
- Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.ACS medicinal chemistry letters · 2014Article
- A neuroendocrine mechanism of co-morbidity of depression-like behavior and myocardial injury in rats.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present clinical positron emission tomography study was to examine if the 5-HTT is a common target, both for tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). Serotonin transporter (5-HTT) occupancy was estimated during treatment with TCA, SSRI and mirtazapine in 20 patients in remission from depression. The patients were recruited from out-patient units and deemed as responders to antidepressive treatment. The radioligand [¹¹C]MADAM was used to determine the 5-HTT binding potential. The mean 5-HTT occupancy was 67% (range 28-86%). There was no significant difference in 5-HTT occupancy between TCA (n=5) and SSRI (n=14). 5-HTT affinity correlated with the recommended clinical dose. Mirtazapine did not occupy the serotonin transporter. The results support that TCAs and SSRIs have a shared mechanism of action by inhibition of 5-HTT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.